Clostridium difficile recurrence is a strong predictor of 30-day rehospitalization among patients in intensive care

Infection Control and Hospital Epidemiology

Volumn 36, Issue 3, 2015, Pages 273-279

  Zilberberg, Marya D ^a,b   Shorr, Andrew F ^c   Micek, Scott T ^d   Kollef, Marin H ^e  

^a EviMed Research Group LLC   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d ST LOUIS COLLEGE OF PHARMACY   (United States)

^e BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEPHALOSPORIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; LINEZOLID; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE; VANCOMYCIN;

ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; CLINICAL TRIAL; CRITICAL ILLNESS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTENSIVE CARE; ISOLATION AND PURIFICATION; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CLOSTRIDIUM DIFFICILE; CRITICAL CARE; CRITICAL ILLNESS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT READMISSION; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84923370803     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1017/ice.2014.47     Document Type: Article

References (37)

1. Compare your country—health profile. United States Organization for Economic Cooperation and Development website. http://www.compareyourcountry.org/health/health-spending-gdp?cr= oecd&lg=en. Accessed April 16, 2014
2. Institute of Medicine. To Err is Human: Building a Safer Health System (Washington: National Academies Press, 1999)
3. Zimlichman E, Henderson D, Tamir O. Franz C, Song P, Yamin C, Keohane C, Denham CR, Bates DW. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039-2046
4. Readmission reduction program. Centers for Medicare and Medicaid Services, Department of Health and Human Services website. http://www.cms.gov/Medicare/Medicare-Fee-for-Service- Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html. Accessed April 14, 2014
5. Magill SS, Edwards JR, Wendy Bamberg W, et al. for the Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-1208
6. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the Healthcare System. Clin Infect Dis 2012;55:S88-S92
7. Pépin JL, Valiquette L, Abary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-472
8. Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007;45:1266-1273
9. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415
10. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14:929-931
11. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441
12. Hudson M. Statistical bulletin—deaths involving Clostridium difficile: England & Wales 2009. Newport, Wales: Office for National Statistics, 2010
13. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449
14. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficileassociated disease in Quebec. Clin Infect Dis 2007;44:238-244
15. Zilberberg MD, Nathanson BH, Sadigov S, et al. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest 2009;136:752-758
16. Micek ST, Schramm G, Morrow L, et al. Clostridium difficile infection: a multicenter study of epidemiology and outcomes in mechanically ventilated patients. Crit CareMed 2013;41:1968-1975
17. Lawrence SJ, Puzniak LA, Shadel BN, et al. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007;28:123-130
18. Lagu T, Stefan MS, Haessler S, Higgins TL, Rothberg MB, Nathanson BH, Hannon NS, Steingrub JS, Lindenauer PK. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. J Hosp Med 2014 Apr 9. DOI 10.1002/jhm.2199 [Epub ahead of print]
19. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455
20. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829
21. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011;140:1643-1653
22. Shorr AF, Zilberberg MD, Reichley R, et al. Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals. Clin Infect Dis 2013;57: 362-367
23. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70:298-304
24. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-333
25. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20: 43-50
26. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007;64: 2359-2363
27. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroentetol 2010;16:3573-3577
28. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012; 46:397-400
29. Prkno A, Wacher C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and metaanalysis. Critical Care 2013;17:R291
30. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (proreal). Arch Intern Med 2012;172:715-722
31. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
32. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-431
33. Cornely OA, Crook DW, Esposito R, et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a doubleblind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-289
34. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014 Jan 16. [Epub ahead of print]
35. Lofgren ET, Moehring RW, Anderson DJ, Weber DJ, Fefferman NH. Amathematicalmodel to evaluate the routine use of fecalmicrobiota transplantation to prevent incident and recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2013;35:18-27
36. Rao K, Young VB, Aronoff DM. Commentary: Fecal microbiota therapy: ready for prime time? Infect Control Hosp Epidemiol 2014;35:28-30
37. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med 2014;9:418-423